## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average bu	ırden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)															
1. Name and Address of Reporting Person *- Hwang Si Moon				2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RNN]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner				
(Last) (First) (Middle) C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455				3. Date of Earliest Transaction (Month/Day/Year) 06/18/2012										ive title below)		ther (specify be	low)
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person					
ROCKVI	LLE, MD	20850											Form filed b	y More than One	Reporting Perso	on	
(Cit	y)	(State)	(Zip)			Tal	ble I -	Non-	-Deriv	ative S	ecurities	Acqui	red, Dispos	ed of, or Ben	eficially Ov	vned	
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Yea		2A. Deemed Execution Date, i r) any (Month/Day/Yea		ate, if	(Instr. 8)		(	4. Securities Acq (A) or Disposed (Instr. 3, 4 and 5)		of (D) Owned Fo		on(s)		Ownership Form:	7. Nature of Indirect Beneficial Ownership		
							Cod	le	V	Amount	(A) or (D)	Price				or Indirect (I) (Instr. 4)	(Instr. 4)
Common	Stock												341,198			D	
Common	on Stock												7,000			I	By daughter
Common	ommon Stock												7,000			I	By daughter
Common	Stock												7,000		I	By Son	
			Table II - I	Derivativ									Owned				
1. Title of Derivative Security (Instr. 3)	Conversion Date Execution Date or Exercise (Month/Day/Year) any		3A. Deemed Execution Date, it	4. 5. Nu Grant St.			umber 6. Date Expirat (Month urities uired or bosed of tr. 3, 4,			e Exercisable and attion Date h/Day/Year)		Amount of Underlying Securities (Instr. 3 and 4)			F 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersl Form of Derivati Security Direct (I or Indire	tive Ownersh y: (Instr. 4)
				Code	V	(A)	(D)			Expi le Date	ration	Title	Amour or Number of Shares				
Stock Options (right- to-buy)	\$ 0.38	06/18/2012		A		20,00	0		(1)	06/1	8/2022	Comr Stoo		\$ 0	20,000	D	
Repor	ting O	wners															

D (1 0 N / 11)	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Hwang Si Moon C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE, MD 20850	X						

### **Signatures**

/s/ Tae Heum Jeong, as attorney-in-fact for Si Moon Hwang	06/26/2012
**Signature of Reporting Person	Date

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intertional misstatements commissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.